Sophiris, Stock Sliding After Cancer Drug Data, Still Plans Phase 3

Sophiris, Stock Sliding After Cancer Drug Data, Still Plans Phase 3

Source: 
Xconomy
snippet: 

Sophiris Bio said Monday that 10 patients who were administered its experimental prostate cancer drug a second time didn’t see any additional benefit.